Cindy M Liu1, Zoe R Packman2, Alison G Abraham3,4, David M Serwadda5, Fred Nalugoda5, Maliha Aziz1, Jessica L Prodger6, Rupert Kaul7, Sarah Kalibbala5, Ronald H Gray3,5, Lance B Price1, Thomas C Quinn8,9, Aaron Ar Tobian2,5, Steven J Reynolds8,9. 1. Department of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC. 2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 5. Rakai Health Sciences Program, Kalisizo, Uganda. 6. Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 7. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 8. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 9. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: The impact of antiretroviral therapy (ART) initiation on the vaginal microbiome is unknown. This is of particular importance among women living in sub-Saharan Africa. Understanding this relationship could help elucidate if and how the host immune system interacts with the vaginal microbiome. METHODS: The vaginal microbiome of HIV-1/HSV-2-coinfected women (n = 92) in Uganda was evaluated from self-collected vaginal swabs 1 month pre-ART and at 4 and 6 months post-ART initiation. The vaginal microbiome was characterized by 16S rRNA gene-based sequencing and quantitative polymerase chain reaction. Vaginal community state types (CSTs) were identified using proportional abundance data. Changes in microbiome composition were assessed with permutational analyses of variance (PerMANOVA). RESULTS: Five vaginal CSTs were identified, which varied significantly by bacterial load (P < .01): CST-1 was characterized by Lactobacillus iners, CST-2 by Gardnerella, CST-3 by Gardnerella and Prevotella, CST-4 by Lactobacillus crispatus, and CST-5 was highly diverse. Vaginal microbiome composition also did not change significantly after ART initiation (P = .985). Immune reconstitution after ART initiation did not affect vaginal microbiome CST assignment (P = .722) or individual-level changes in bacterial load (log response ratio [interquartile range], -0.50 [-2.75 to 0.38] vs -0.29 [-2.03 to 1.42]; P = .40). CONCLUSIONS: The vaginal microbiome of HIV-infected women was not affected by the initiation of ART or immune reconstitution in this observational study. Further research is needed to explore the long-term effects of ART treatment on the vaginal microbiome. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019.
BACKGROUND: The impact of antiretroviral therapy (ART) initiation on the vaginal microbiome is unknown. This is of particular importance among women living in sub-Saharan Africa. Understanding this relationship could help elucidate if and how the host immune system interacts with the vaginal microbiome. METHODS: The vaginal microbiome of HIV-1/HSV-2-coinfected women (n = 92) in Uganda was evaluated from self-collected vaginal swabs 1 month pre-ART and at 4 and 6 months post-ART initiation. The vaginal microbiome was characterized by 16S rRNA gene-based sequencing and quantitative polymerase chain reaction. Vaginal community state types (CSTs) were identified using proportional abundance data. Changes in microbiome composition were assessed with permutational analyses of variance (PerMANOVA). RESULTS: Five vaginal CSTs were identified, which varied significantly by bacterial load (P < .01): CST-1 was characterized by Lactobacillus iners, CST-2 by Gardnerella, CST-3 by Gardnerella and Prevotella, CST-4 by Lactobacillus crispatus, and CST-5 was highly diverse. Vaginal microbiome composition also did not change significantly after ART initiation (P = .985). Immune reconstitution after ART initiation did not affect vaginal microbiome CST assignment (P = .722) or individual-level changes in bacterial load (log response ratio [interquartile range], -0.50 [-2.75 to 0.38] vs -0.29 [-2.03 to 1.42]; P = .40). CONCLUSIONS: The vaginal microbiome of HIV-infected women was not affected by the initiation of ART or immune reconstitution in this observational study. Further research is needed to explore the long-term effects of ART treatment on the vaginal microbiome. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2019.
Authors: Jennifer M Fettweis; J Paul Brooks; Myrna G Serrano; Nihar U Sheth; Philippe H Girerd; David J Edwards; Jerome F Strauss; Kimberly K Jefferson; Gregory A Buck Journal: Microbiology (Reading) Date: 2014-07-29 Impact factor: 2.777
Authors: Roberto Romero; Sonia S Hassan; Pawel Gajer; Adi L Tarca; Douglas W Fadrosh; Lorraine Nikita; Marisa Galuppi; Ronald F Lamont; Piya Chaemsaithong; Jezid Miranda; Tinnakorn Chaiworapongsa; Jacques Ravel Journal: Microbiome Date: 2014-02-03 Impact factor: 14.650
Authors: Hanneke Borgdorff; Charlotte van der Veer; Robin van Houdt; Catharina J Alberts; Henry J de Vries; Sylvia M Bruisten; Marieke B Snijder; Maria Prins; Suzanne E Geerlings; Maarten F Schim van der Loeff; Janneke H H M van de Wijgert Journal: PLoS One Date: 2017-07-11 Impact factor: 3.240
Authors: Richard G Brown; Maya Al-Memar; Julian R Marchesi; Yun S Lee; Ann Smith; Denise Chan; Holly Lewis; Lindsay Kindinger; Vasso Terzidou; Tom Bourne; Phillip R Bennett; David A MacIntyre Journal: Transl Res Date: 2018-12-27 Impact factor: 7.012
Authors: Martha C Nason; Eshan U Patel; Allison R Kirkpatrick; Jessica L Prodger; Kamnoosh Shahabi; Aaron A R Tobian; Sara Gianella; Sarah Kalibbala; Paschal Ssebbowa; Rupert Kaul; Ronald H Gray; Thomas C Quinn; David Serwadda; Steven J Reynolds; Andrew D Redd Journal: Open Forum Infect Dis Date: 2016-04-06 Impact factor: 3.835